GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (STU:NPAU) » Definitions » Cyclically Adjusted Price-to-FCF

BetterLife Pharma (STU:NPAU) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BetterLife Pharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


BetterLife Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BetterLife Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma Cyclically Adjusted Price-to-FCF Chart

BetterLife Pharma Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BetterLife Pharma Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BetterLife Pharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, BetterLife Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's Cyclically Adjusted Price-to-FCF falls into.



BetterLife Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BetterLife Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, BetterLife Pharma's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.002/125.0724*125.0724
=-0.002

Current CPI (Jan. 2024) = 125.0724.

BetterLife Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201404 -0.001 98.920 -0.001
201407 0.003 99.315 0.004
201410 -0.007 99.473 -0.009
201501 -0.028 98.209 -0.036
201504 -0.002 99.710 -0.003
201507 -0.003 100.579 -0.004
201510 -0.013 100.500 -0.016
201601 -0.001 100.184 -0.001
201604 -0.009 101.370 -0.011
201607 -0.005 101.844 -0.006
201610 -0.018 102.002 -0.022
201701 -0.012 102.318 -0.015
201704 -0.008 103.029 -0.010
201707 -0.004 103.029 -0.005
201710 -0.011 103.424 -0.013
201801 -0.022 104.056 -0.026
201804 -0.180 105.320 -0.214
201807 -0.069 106.110 -0.081
201810 -0.069 105.952 -0.081
201901 -0.031 105.557 -0.037
201904 -0.028 107.453 -0.033
201907 -0.190 108.243 -0.220
201910 -0.061 107.927 -0.071
202001 -0.061 108.085 -0.071
202004 -0.052 107.216 -0.061
202007 -0.029 108.401 -0.033
202010 -0.054 108.638 -0.062
202101 -0.033 109.192 -0.038
202104 -0.035 110.851 -0.039
202107 -0.038 112.431 -0.042
202110 -0.017 113.695 -0.019
202201 -0.016 114.801 -0.017
202204 -0.003 118.357 -0.003
202207 -0.003 120.964 -0.003
202210 -0.005 121.517 -0.005
202301 -0.001 121.596 -0.001
202304 -0.009 123.571 -0.009
202307 -0.003 124.914 -0.003
202310 -0.002 125.310 -0.002
202401 -0.002 125.072 -0.002

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BetterLife Pharma  (STU:NPAU) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BetterLife Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BetterLife Pharma (STU:NPAU) Business Description

Industry
Traded in Other Exchanges
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.

BetterLife Pharma (STU:NPAU) Headlines

No Headlines